Prevention of Bone Mineral Loss in Postmenopausal Women by Norethisterone

Overview

Journal Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 1985 Dec 1

PMID 4069480

Citations 16

Authors

H I Abdalla

D M Hart

R Lindsay

I Leggate

A Hooke

Affiliations

Soon will be listed here.

Abstract

The effect of norethisterone on bone mineral metabolism was examined in 43 postmenopausal women. A significant decline in serum calcium, phosphate, and alkaline phosphatase in urinary calcium/creatinine ratio and in tubular maximum reabsorption of phosphate was demonstrated. There was no alteration in urinary hydroxyproline/creatinine ratio. The bone mineral content measured over two years by single photon absorptiometry was compared in 20 patients receiving norethisterone and a matched control group receiving placebo. There was significant protection against bone loss in the norethisterone group.

Citing Articles

Progestogens in menopausal hormone therapy.

Binkowska M, Woron J Prz Menopauzalny. 2015; 14(2):134-43.

PMID: 26327902 PMC: 4498031. DOI: 10.5114/pm.2015.52154.

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Stanczyk F, Hapgood J, Winer S, Mishell Jr D Endocr Rev. 2012; 34(2):171-208.

PMID: 23238854 PMC: 3610676. DOI: 10.1210/er.2012-1008.

The strategy for the treatment of osteoporosis.

Christiansen C Osteoporos Int. 1997; 7 Suppl 3:S147-9.

PMID: 9536321 DOI: 10.1007/BF03194361.

Osteoporosis prevention.

Drew S Br J Gen Pract. 1998; 47(423):663.

PMID: 9474844 PMC: 1410126.

Differentiation of osteoblast in vitro is regulated by progesterone.

Chen L, Foged N J Tongji Med Univ. 1996; 16(2):83-6.

PMID: 9275698 DOI: 10.1007/BF02887963.